RT Journal Article
SR Electronic
T1 Seroprevalence of SARS-CoV-2 antibodies in broadcast media workers
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.29.21256360
DO 10.1101/2021.04.29.21256360
A1 Martins-Filho, Paulo Ricardo
A1 da Silva, Danilo Nobre
A1 Santos, Danillo Menezes dos
A1 Rezende, Márcia Santos
A1 Silva, Jessica Paloma Rosa
A1 da Silva Neto, Josafá Bonifácio
A1 Schimieguel, Dulce Marta
A1 Quintans-Júnior, Lucindo José
A1 de Souza Siqueira Quintans, Jullyana
A1 Nunes, Paula Santos
A1 de Sousa Araújo, Adriano Antunes
YR 2021
UL http://medrxiv.org/content/early/2021/05/02/2021.04.29.21256360.abstract
AB In this cross-sectional study, we investigated the seroprevalence of SARS-CoV-2 antibodies in workers of radio and television (TV) in Sergipe state, Northeast Brazil. The study was conducted from December 1 to December 20, 2020, considered the beginning of the second wave of COVID-19 in the state. Our findings showed a high seroprevalence of SARS-CoV-2 antibodies in radio and TV workers, especially among those in the production and operation teams. Prevention and control protocols against COVID-19 should be revised and implemented by media companies. Broadcast media workers should be prioritized in COVID-19 vaccine strategies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementTo all frontline workers who are facing the COVID-19 pandemic. This study is part of the EpiSERGIPE project which is supported by grant SES/FAPESE/UFS 001/2020. The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethics Committee of the Federal University of Sergipe (protocol number 33095120.4.0000.5546).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request from the corresponding author.